The company we keep: Why physicians should refuse to see pharmaceutical representatives

Annals of Family Medicine

Volumn 3, Issue 1, 2005, Pages 82-85

  Brody, Howard ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Drug industry; Ethics; Health care delivery; Health services research

Indexed keywords

CLINICAL PRACTICE; CLINICAL RESEARCH; DRUG CHOICE; DRUG INDUSTRY; HUMAN; MEDICAL ETHICS; PHYSICIAN; PRACTICE GUIDELINE; PUBLIC OPINION; RESPONSIBILITY; REVIEW; TIME MANAGEMENT;

COMMERCE; DRUG INDUSTRY; PHYSICIANS;

EID: 13444263830     PISSN: 15441709     EISSN: None     Source Type: Journal    
DOI: 10.1370/afm.259     Document Type: Review

References (24)

1. Sebra J. Drug reps and doctors took an undeserved hit. Wall Street Journal. July 12, 2002: A9.
2. Rothman DJ. Medical professionalism-focusing on the real issues. N Engl J Med. 2000;342:1283-1286.
3. Schafer A. Biomedical conflicts of interest: a defence of the sequestration thesis-learning from the cases of Nancy Olivieri and David Healy. J Med Ethics. 2004;30:8-24.
4. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest. 1992;102:270-273.
5. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373-380.
6. Reviews: What impact does pharmaceutical promotion have on behavior? Drug Promotion Database. Available at: http://www.drug-promo.info/read-reviews.asp? id=4. Accessed 29 April 2004.
7. Figueiras A, Caamano F, Gestal-Otero JJ. Influence of physician's education, drug information and medical-care settings on the quality of drugs prescribed. Eur J Clin Pharmacol. 2000;56:747-753.
8. Zweifler J, Hughes S, Schafer S, et al. Are sample medicines hurting the uninsured? J Am Board Fam Pract. 2002;15:361-366.
9. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982;73:4-8.
10. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2003;290:252-255.
11. Chren MM, Landefeld CS, Murray TH. Doctors, drug companies, and gifts. JAMA. 1989;262:3448-3451.
12. Rosenthal MB, Berndt ER, Donahue JM, et al. Promotion of prescription drugs to consumers. N Engl J Med. 2002;346:498-505.
13. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995;273:1296-1298.
14. Murphy S. Gifts seen as effective by drug company reps. Boston Globe. Nov. 17, 2002: B1.
15. Griffith D. Reasons for not seeing drug representatives. BMJ. 1999;319:69-70.
16. Kassirer JP. A piece of my mind: financial indigestion. JAMA. 2000;284:2156-2157.
17. Westfall JM, McCabe J, Nicholas RA. Personal use of drug samples by physicians and office staff. JAMA. 1997;278:141-143.
18. Erickson S. Closing the sample closet: How well could you get along without medication samples-and without drug reps? Very well, according to the authors. Fam Pracf Management. 1995;2:43-47.
19. Chew LD, O'Young TS, Hazlet TK, et al. A physician survey of the effect of drug sample availability on physicians' behavior. J Gen Intern Med. 2000;15:478-483.
20. Westfall JM. Physicians, pharmaceutical representatives, and patients: who really benefits? J Fam Pract. 2000;49:817-819.
21. Hensley S. Sorry, Doc, no dinners-to-go: drug sales reps begin building a new marketing playbook. Wall Street Journal. April 23, 2002:D4.
22. Pear R. Drug industry is told to stop gifts to doctors. New York Times. Oct. 1, 2002:A1.
23. Coyle SL. Physician-industry relations. Part 1: individual physicians. Ann Intern Med. 2002;136:396-402.
24. May CD. Selling drugs by "educating" physicians. J Med Educ. 1961;36:1-23.